Testing effectiveness (Phase 2)Study completedNCT02035813
What this trial is testing
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Who this might be right for
HER2-negative and Hormone-receptor Positive Metastatic Breast CancerHER2-negative Circulating Tumor CellsPostmenopausal Female Patients
Prof. Wolfgang Janni 116